Metropolitan Life Insurance CO Jounce Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $46,144 - $65,570	-7,678 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$7.11 - $9.64 $54,590 - $74,015	7,678 New	7,678 $64,000
Q4 2021 Mar 30, 2023	SELL	$7.11 - $9.64 $13,437 - $18,219	-1,890 Reduced 19.75%	7,678 $64,000
Q4 2021 Feb 15, 2022	SELL	$7.11 - $9.64 $13,437 - $18,219	-1,890 Reduced 19.75%	7,678 $64,000
Q3 2021 Jun 21, 2023	BUY	$5.04 - $8.73 $48,222 - $83,528	9,568 New	9,568 $71,000
Q3 2021 Mar 30, 2023	BUY	$5.04 - $8.73 $48,222 - $83,528	9,568 New	9,568 $71,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $48,222 - $83,528	9,568 New	9,568 $71,000
Q2 2018 Aug 15, 2018	SELL	$7.27 - $21.88 $36,459 - $109,728	-5,015 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $67,201 - $142,426	5,015 New	5,015 $0
Q4 2017 Feb 15, 2018	SELL	$12.52 - $17.82 $138,884 - $197,677	-11,093 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $123,908 - $188,470	11,093	11,093 $173,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.